

# Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/TC47896FB39BEN.html>

Date: July 2020

Pages: 102

Price: US\$ 3,500.00 (Single User License)

ID: TC47896FB39BEN

## Abstracts

Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020

### SUMMARY

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF- $\beta$ 1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 31 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 1, 12 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Ophthalmology, Respiratory, Gastrointestinal, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Cardiovascular, Central Nervous System, Genetic Disorders, Hematological Disorders, Infectious Disease, Male Health and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Corneal Dystrophy, Hepatocellular Carcinoma, Kidney Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Non-

Small Cell Lung Cancer, Osteoarthritis, Primary Sclerosing Cholangitis, Squamous Cell Carcinoma, Acute Respiratory Distress Syndrome, Age Related Macular Degeneration, Anemia, Benign Prostatic Hyperplasia, Bladder Cancer, Bone Disorders, Cholangitis, Coronavirus Disease 2019 (COVID-19), Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hyperalgesia, Hypertrophic Scars, Inflammation, Keloids, Liver Fibrosis, Lung Adenocarcinoma, Melanoma, Metastatic Breast Cancer, Myelofibrosis, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatic Cancer, Pancreatitis Pain, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension, Scar, Systemic Sclerosis (Scleroderma), Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).

The latest report Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)

The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transforming

## Growth Factor Beta 1 (TGFB1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Transforming Growth Factor Beta 1 (TGFB1) - Overview

Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development

Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment

Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics  
Development

Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles

Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products

Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products

Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Indications, H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020  
Number of Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020  
Number of Products under Investigation by Universities/Institutes, H2 2020  
Products under Investigation by Universities/Institutes, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Pipeline by Aiviva BioPharma Inc, H2 2020  
Pipeline by Avacta Life Sciences Ltd, H2 2020  
Pipeline by Avellino Lab USA Inc, H2 2020  
Pipeline by Bonac Corp, H2 2020  
Dormant Products, H2 2020  
Dormant Products, H2 2020 (Contd..1), H2 2020  
Dormant Products, H2 2020 (Contd..2), H2 2020  
Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Top 10 Indications, H2 2020  
Number of Products by Mechanism of Actions, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Top 10 Routes of Administration, H2 2020  
Number of Products by Stage and Top 10 Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

Aiviva BioPharma Inc  
Avacta Life Sciences Ltd  
Avellino Lab USA Inc  
Bonac Corp  
Ensol Biosciences Inc  
Forbius  
Genzyme Corp  
Huabo Biopharm Co Ltd  
Isarna Therapeutics GmbH  
Johnson & Johnson  
Nanjing Shenghe Pharmaceutical Co Ltd  
Novartis AG  
Phio Pharmaceuticals Corp  
Scholar Rock Inc  
Sirnaomics Inc  
Sisaf Ltd

## I would like to order

Product name: Transforming Growth Factor Beta 1 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/TC47896FB39BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TC47896FB39BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970